Article Details
Retrieved on: 2024-11-18 22:38:48
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses TrueBinding's development of TB006, a monoclonal antibody targeting Galectin-3, for treating neurodegenerative diseases like Parkinson's and Alzheimer's, highlighting its potential cognitive benefits in Alzheimer's, relating to the tags and Alzheimer's key concept.
Article found on: www.globenewswire.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here